nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2014

Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

verfasst von: Soo Hyung Ryu, Myoung Kuk Jang, Woo Jean Kim, Danbi Lee, Young-Hwa Chung

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC), a prototype of hypervascular tumors, is one of the most common malignancies in the world, especially hyperendemic in the Far East where chronic hepatitis B virus (HBV) infection is highly prevalent. It is characterized by the clinical feature of a poor prognosis or a high mortality due to its already far advanced stages at diagnosis. It is so multifactorial that hepatocarcinogenesis cannot be explained by a single molecular mechanism. To date, a number of pathways have been known to contribute to the development, growth, angiogenesis, and even metastasis of HCC. Among the various factors, metastatic tumor antigens (MTAs) or metastasis-associated proteins have been vigorously investigated as an intriguing target in the field of hepatocarcinogenesis. According to recent studies including ours, MTAs are not only involved in the HCC development and growth (molecular carcinogenesis), but also closely associated with the post-operative recurrence and a poor prognosis or a worse response to post-operative anti-cancer therapy (clinical significance). Herein, we review MTAs in light of their essential structure, functions, and molecular mechanism in hepatocarcinogenesis. We will also focus in detail on the interaction between hepatitis B x protein (HBx) of HBV and MTA in order to clarify the HBV-associated HCC development. Finally, we will discuss the prognostic significance and clinical application of MTA in HCC. We believe that this review will help clinicians to understand the meaning and use of the detection of MTA in order to more effectively manage their HCC patients.

Bosch, F. X., Ribes, J., Diaz, M., & Cleries, R. (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127(5 Suppl 1), S5–S16.PubMed

Kiyosawa, K., Umemura, T., Ichijo, T., Matsumoto, A., Yoshizawa, K., Gad, A., et al. (2004). Hepatocellular carcinoma: recent trends in Japan. Gastroenterology, 127(5 Suppl 1), S17–S26.PubMed

El-serag, H. B. (2004). Hepatocellular carcinoma: recent trends in the United States. Gastroenterology, 127(5 Suppl 1), S27–S34.PubMed

Chen, M. F., Hwang, T. L., Jeng, L. B., Jan, Y. Y., Wang, C. S., & Chou, F. F. (1989). Hepatic resection in 120 patients with hepatocellular carcinoma. Archives of Surgery, 124(9), 1025–1028.PubMed

Tsuzuki, T., Sugioka, A., Ueda, M., Iida, S., Kanai, T., Yoshii, H., et al. (1990). Hepatic resection for hepatocellular carcinoma. Surgery, 107(5), 511–520.PubMed

Nagorney, D. M., van Heerden, J. A., Ilstrup, D. M., & Adson, M. A. (1989). Primary hepatic malignancy: surgical management and determinants of survival. Surgery, 106(4), 740–748.PubMed

Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 30(6), 1434–1440.PubMed

Okada, S., Shimada, K., Yamamoto, J., Takayama, T., Kosuge, T., Yamasaki, S., et al. (1994). Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology, 106(6), 1618–1624.PubMed

Adachi, E., Maeda, T., Matsumata, T., Shirabe, K., Kinukawa, N., Sugimachi, K., et al. (1995). Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology, 108(3), 768–775.PubMed

10.

Kumada, T., Nakano, S., Takeda, I., Sugiyama, K., Osada, T., Kiriyama, S., et al. (1997). Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology, 25(1), 87–92.PubMed

11.

Mahoney, M. G., Simpson, A., Jost, M., Noe, M., Kari, C., Pepe, D., et al. (2002). Metastasis-associated protein (MTA) 1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene, 21(14), 2161–2170.PubMed

12.

Hofer, M. D., Menke, A., Genze, F., Gierschik, P., & Giehl, K. (2004). Expression of MTA1 promotes motility and invasiveness of PNAC-1 pancreatic carcinoma cells. British Journal of Cancer, 90(2), 455–462.PubMedCentralPubMed

13.

Nicolson, G. L., Nawa, A., Toh, Y., Taniguchi, S., Nishimori, K., & Moustafa, A. (2003). Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer invasion, proliferation and nuclear regulation. Clinical and Experimental Metastasis, 20(1), 19–24.PubMed

14.

Moon, H. E., Cheon, H., Chun, K. H., Lee, S. K., Kim, Y. S., Jung, B. K., et al. (2006). Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncology Reports, 16(4), 929–935.PubMed

15.

Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25(6), 1231–1241.PubMedCentralPubMed

16.

Kim, S. H., Jeong, J. W., Park, J. A., Lee, J. W., Seo, J. H., Jung, B. K., et al. (2007). Regulation of the HIF-1alpha stability by histone deacetylases. Oncology Reports, 17(3), 647–651.PubMed

17.

Jang, K. S., Paik, S. S., Chung, H. K., Oh, Y. H., & Kong, G. (2006). MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancer. Cancer Science, 97(5), 374–379.PubMed

18.

Martin, M. D., Hilsenbeck, S. G., Mohsin, S. K., Hopp, T. A., Clark, G. M., Osborne, C. K., et al. (2006). Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 95(1), 7–12.PubMed

19.

Hofer, M. D., Kuefer, R., Varambally, S., Li, H., Ma, J., Shapiro, G. I., et al. (2004). The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Research, 64(3), 825–829.PubMed

20.

Toh, Y., Ohga, T., Endo, K., Adachi, E., Kusumoto, H., Haraguchi, M., et al. (2004). Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. International Journal of Cancer, 110(3), 362–367.

21.

Balasenthil, S., Broaddus, R. R., & Kumar, R. (2006). Expression of metastasis-associated protein 1 (MTA1) in benign endometrium and endometrial adenocarcinomas. Human Pathology, 37(6), 656–661.PubMed

22.

Toh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., et al. (1997). Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. International Journal of Cancer, 74(4), 459–463.

23.

Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Yukiue, H., Kaji, M., et al. (2002). Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer, 35(2), 149–154.PubMed

24.

Kumar, R., Wang, R. A., & Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Seminars in Oncology, 30(5 suppl 16), 30–37.PubMed

25.

Moon, W. S., Chang, K., & Tarnawski, A. S. (2004). Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-α. Human Pathology, 35(4), 424–429.PubMed

26.

Hamatsu, T., Rikimaru, T., Yamashita, Y., Aishima, S., Tanaka, S., Shirabe, K., et al. (2003). The role of MTA1 gene expression in human hepatocellular carcinoma. Oncology Reports, 10(3), 599–604.PubMed

27.

Ryu, S. H., Chung, Y. H., Lee, H., Kim, J. A., Shin, H. D., Min, H. J., et al. (2008). Metastatic tumor antigen 1 is closely associated with frequent post-operative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology, 47(3), 929–936.PubMed

28.

Lee, H., Ryu, S. H., Hong, S. S., Seo, D. D., Min, H. J., Jang, M. K., et al. (2009). Overexpression of metastasis-associated protein 2 is associated with hepatocellular carcinoma size and differentiation. Journal of Gastroenterology and Hepatology, 24(8), 1445–1450.PubMed

29.

Lee, S. H., Chung, Y. H., Kim, J. A., Lee, D., Jin, Y. J., Shim, J. H., et al. (2011). Single nucleotide polymorphisms associated with metastatic tumor antigen 1 overexpression in patients with hepatocellular carcinoma. Liver International, 32(3), 457–466.PubMed

30.

Jin, Y. J., Chung, Y. H., Kim, J. A., Park, W. H., Lee, D., Seo, D. D., et al. (2012). Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma. Digestive Diseases and Sciences, 57(11), 2917–2923.PubMed

31.

Lee, D., Chung, Y. H., Kim, J. A., Park, W. H., Jin, Y. J., Shim, J. H., et al. (2013). Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer, 119(12), 2239–2246.PubMed

32.

Yao, Y. L., & Yang, W. M. (2003). The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. Journal of Biological Chemistry, 278(43), 42560–42568.PubMed

33.

Toh, Y., Pencil, S. D., & Nicolson, G. L. (1995). Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines. Gene, 159(1), 97–104.PubMed

34.

Pencil, S. D., Toh, Y., & Nicolson, G. L. (1993). Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinoma. Breast Cancer Research and Treatment, 25(2), 165–174.PubMed

35.

Toh, Y., & Nicolson, G. L. (2009). The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clinical and Experimental Metastasis, 26(3), 215–227.PubMed

36.

Manavathi, B., & Kumar, R. (2007). Metastasis tumor antigens, an emerging family of multifaceted master coregulators. Journal of Biological Chemistry, 282(3), 1529–1533.PubMed

37.

Nawa, A., Nishimori, K., Lin, P., Maki, Y., Moue, K., Sawada, H., et al. (2000). Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides. Journal of Cellular Biochemistry, 79(2), 202–212.PubMed

38.

Singh, R. R., & Kumar, R. (2007). MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 115–125.PubMed

39.

Pawson, T., & Schlessingert, J. (1993). SH2 and SH3 domains. Current Biology, 3(7), 434–442.PubMed

40.

Bar-Sagi, D., Rotin, D., Batzer, A., Mandiyan, V., & Schlessinger, J. (1993). SH3 domains direct cellular localization of signaling molecules. Cell, 74(1), 83–91.PubMed

41.

Weng, Z., Taylor, J. A., Turner, C. E., Brugge, J. S., & Seidel-Dugan, C. (1993). Detection of Src homology 3-binding proteins, including paxillin, in normal and v-Src-transformed Balb/c 3T3 cells. Journal of Biological Chemistry, 268(20), 14956–14963.PubMed

42.

Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269(37), 22958–22963.PubMed

43.

Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z., et al. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature, 418(6898), 654–657.PubMed

44.

Li, W., Ma, L., Zhao, J., Liu, X., Li, Z., & Zhang, Y. (2009). Expression profile of MTA1 in adult mouse tissues. Tissue and Cell, 41(6), 390–399.PubMed

45.

Liu, J., Xu, D., Wang, H., Zhang, Y., Chang, Y., Zhang, J., et al. (2014). The subcellular distribution and function of MTA1 in cancer differentiation. Oncotarget, 5(13), 5153–5164.PubMedCentralPubMed

46.

Nagaraj S. R., Shilpa P., Rachaiah K., Salimath B.P. (2013). Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma. Molecular Carcinogenesis, 2013 Nov 22. doi: 10.1002/mc.22104

47.

Neuveut, C., Wei, Y., & Buendia, M. A. (2010). Mechanisms of HBV-related hepatocarcinogenesis. Journal of Hepatology, 52(4), 594–604.PubMed

48.

Murakami, S. (2001). Hepatitis B virus X protein: a multifunctional viral regulator. Journal of Gastroenterology, 36(10), 651–660.PubMed

49.

Zhang, X., Zhang, H., & Ye, L. (2006). Effects of hepatitis B virus X protein on the development of liver cancer. Journal of Laboratory and Clinical Medicine, 147(2), 58–66.PubMed

50.

Yun, C., Um, H. R., Jin, Y. H., Wang, J. H., Lee, M. O., Park, S., et al. (2002). NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Letters, 184(1), 97–104.PubMed

51.

Chan, D. W., & Ng, I. O. (2006). Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. Journal of Pathology, 208(3), 372–380.PubMed

52.

Yoo, Y. G., Na, T. Y., Seo, H. W., Seong, J. K., Park, C. K., Shin, Y. K., et al. (2008). Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 27(24), 3405–3413.PubMed

53.

Feitelson, M. A., & Lee, J. (2007). Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Letters, 252(2), 157–170.PubMed

54.

Liu, B., Wen, X., Huang, C., & Wei, Y. (2013). Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. International Journal of Biochemistry and Cell Biology, 45(9), 1987–1996.PubMed

55.

Wang, F., Zhou, H., Yang, Y., Xia, X., Sun, Q., Luo, J., et al. (2012). Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncology Reports, 27(4), 1170–1176.PubMedCentralPubMed

56.

Lara-Pezzi, E., Roche, S., Andrisani, O. M., Sánchez-Madrid, F., & López-Cabrera, M. (2001). The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene, 20(26), 3323–3331.PubMed

57.

Lara-Pezzi, E., Majano, P. L., Yáñez-Mó, M., Gómez-Gonzalo, M., Carretero, M., Moreno-Otero, R., et al. (2001). Effect of the hepatitis B virus HBx protein on integrin-mediated adhesion to and migration on extracellular matrix. Journal of Hepatology, 34(3), 409–415.PubMed

58.

Lara-Pezzi, E., Gómez-Gaviro, M. V., Gálvez, B. G., Mira, E., Iñiguez, M. A., Fresno, M., et al. (2002). The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. Journal of Clinical Investigation, 110(12), 1831–1838.PubMedCentralPubMed

59.

Chung, T. W., Lee, Y. C., & Kim, C. H. (2004). Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB Journal, 18(10), 1123–1125.PubMed

60.

Yu, F. L., Liu, H. J., Lee, J. W., Liao, M. H., & Shih, W. L. (2005). Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. Journal of Hepatology, 42(4), 520–527.PubMed

61.

Ou, D. P., Tao, Y. M., Chang, Z. G., Tang, F. Q., & Yang, L. Y. (2006). Hepatocellular carcinoma cells containing hepatitis B virus X protein have enhanced invasive potential conditionally. Digestive and Liver Disease, 38(4), 262–267.PubMed

62.

Ou, D. P., Tao, Y. M., Tang, F. Q., & Yang, L. Y. (2007). The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. International Journal of Cancer, 120(6), 1208–1214.

63.

Zhang, X., Liu, S., Hu, T., Liu, S., He, Y., & Sun, S. (2009). Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology, 50(2), 490–499.PubMed

64.

Manavathi, B., Singh, K., & Kumar, R. (2007). MTA family of coregulators in nuclear receptor biology and pathology. Nuclear Receptor Signaling, 5, e010.PubMedCentralPubMed

65.

Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, R. D., Xia, W., Hung, M. C., Sarin, S. K., et al. (2010). NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene, 29(8), 1179–1189.PubMedCentralPubMed

66.

Jung, J. K., Park, S. H., & Jang, K. L. (2010). Hepatitis B virus X protein overcomes the growth-inhibitory potential of retinoic acid by downregulating retinoic acid receptor-beta2 expression via DNA methylation. Journal of General Virology, 91(Pt 2), 493–500.PubMed

67.

Park, I. Y., Sohn, B. H., Yu, E., Suh, D. J., Chung, Y. H., Lee, J. H., et al. (2007). Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology, 132(4), 1476–1494.PubMed

68.

Lee, M. H., Na, H., Na, T. Y., Shin, Y. K., Seong, J. K., & Lee, M. O. (2012). Epigenetic control of metastasis-associated protein 1 gene expression by hepatitis B virus X protein during hepatocarcinogenesis. Oncogenesis, 1, e25.PubMedCentralPubMed

69.

Reddy, S. D., Pakala, S. B., Ohshiro, K., Rayala, S. K., & Kumar, R. (2009). MicroRNA-661, a c/EBPalpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Research, 69(14), 5639–5642.PubMedCentralPubMed

70.

Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, D. R., Martin, E., Murad, F., & Kumar, R. (2010). Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. Journal of Biological Chemistry, 285(10), 6980–6986.PubMedCentralPubMed

71.

Aboobaker, A. A., Tomancak, P., Patel, N., Rubin, G. M., & Lai, E. C. (2005). Drosophila microRNAs exhibit diverse spatial expression patterns during embryonic development. Proceedings of the National Academy of Sciences of the United States of America, 102(50), 18017–18022.PubMedCentralPubMed

72.

Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Research, 65(16), 7065–7070.PubMed

73.

Makeyev, E. V., & Maniatis, T. (2008). Multilevel regulation of gene expression by microRNAs. Science, 319(5871), 1789–1790.PubMedCentralPubMed

74.

Behm-Ansmant, I., Rehwinkel, J., & Izaurralde, E. (2006). MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harbor Symposia on Quantitative Biology, 71, 523–530.PubMed

75.

Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682–688.PubMed

76.

Reddy, S. D., Ohshiro, K., Rayala, S. K., & Kumar, R. (2008). MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Research, 68(20), 8195–8200.PubMedCentralPubMed

77.

Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., et al. (2008). microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Research, 68(10), 3566–3572.PubMed

78.

Li, S., Tian, H., Yue, W., Li, L., Gao, C., Si, L., et al. (2013). Down-regulation of MTA1 protein leads to the inhibition of migration, invasion, and angiogenesis of non-small-cell lung cancer cell line. Acta Biochimica et Biophysica Sinica, 45(2), 115–122.PubMed

79.

Mazure, N. M., Brahimi-Horn, M. C., Berta, M. A., Benizri, E., Bilton, R. L., Dayan, F., et al. (2004). HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochemical Pharmacology, 68(6), 971–980.PubMed

80.

Bruick, R. K., & McKnight, S. L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294(5545), 1337–1340.PubMed

81.

Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O’Rourke, J., Mole, D. R., et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107(1), 43–54.PubMed

82.

Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3(10), 721–732.PubMed

83.

Jeong, J. W., Bae, M. K., Ahn, M. Y., Kim, S. H., Sohn, T. K., Bae, M. H., et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 111(5), 709–720.PubMed

84.

Côté, J., Quinn, J., Workman, J. L., & Peterson, C. L. (1994). Stimulation of GAL4 derivative binding to nucleosomal DNA by the yeast SWI/SNF complex. Science, 265(5168), 53–60.PubMed

85.

Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E., & Green, M. R. (1994). Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature, 370(6489), 477–481.PubMed

86.

Tsukiyama, T., & Wu, C. (1995). Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell, 83(6), 1011–1020.PubMed

87.

Cairns, B. R., Lorch, Y., Li, Y., Zhang, M., Lacomis, L., Erdjument-Bromage, H., et al. (1996). RSC, an essential, abundant chromatin-remodeling complex. Cell, 87(7), 1249–1260.PubMed

88.

Wang, W., Chi, T., Xue, Y., Zhou, S., Kuo, A., & Crabtree, G. R. (1998). Architectural DNA binding by a high-mobility-group/kinesin-like subunit in mammalian SWI/SNF-related complexes. Proceedings of the National Academy of Sciences of the United States of America, 95(2), 492–498.PubMedCentralPubMed

89.

Varga-Weisz, P. D., Wilm, M., Bonte, E., Dumas, K., Mann, M., & Becker, P. B. (1997). Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature, 388(6642), 598–602.PubMed

90.

Xue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Molecular Cell, 2(6), 851–861.PubMed

91.

Nair, S. S., Bommana, A., Bethony, J. M., Lyon, A. J., Ohshiro, K., Pakala, S. B., et al. (2011). The metastasis-associated protein-1 gene encodes a host permissive factor for schistosomiasis, a leading global cause of inflammation and cancer. Hepatology, 54(1), 285–295.PubMedCentralPubMed

92.

Ghanta, K. S., Pakala, S. B., Reddy, S. D., Li, D. Q., Nair, S. S., & Kumar, R. (2011). MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. Journal of Biological Chemistry, 286(9), 7132–7138.PubMedCentralPubMed

93.

Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285(31), 23590–23597.PubMedCentralPubMed

94.

Pakala, S. B., Reddy, S. D., Bui-Nguyen, T. M., Rangparia, S. S., Bommana, A., & Kumar, R. (2010). MTA1 coregulator regulates LPS response via MyD88-dependent signaling. Journal of Biological Chemistry, 285(43), 32787–32792.PubMedCentralPubMed

95.

Li, D. Q., Pakala, S. B., Reddy, S. D., Ohshiro, K., Peng, S. H., Lian, Y., et al. (2010). Revelation of p53-independent function of MTA1 in DNA damage response via modulation of the p21 WAF1-proliferating cell nuclear antigen pathway. Journal of Biological Chemistry, 285(13), 10044–10052.PubMedCentralPubMed

96.

Van Rechem, C., Boulay, G., Pinte, S., Stankovic-Valentin, N., Guérardel, C., & Leprince, D. (2010). Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells. Molecular and Cellular Biology, 30(16), 4045–4059.PubMedCentralPubMed

97.

Wales, M. M., Biel, M. A., el Deiry, W., Nelkin, B. D., Issa, J. P., Cavenee, W. K., et al. (1995). p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Medicine, 1(6), 570–577.PubMed

98.

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 817–825.PubMed

99.

Vitari, A. C., Leong, K. G., Newton, K., Yee, C., O’Rourke, K., Liu, J., et al. (2011). COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature, 474(7351), 403–406.PubMed

100.

Migliorini, D., Bogaerts, S., Defever, D., Vyas, R., Denecker, G., Radaelli, E., et al. (2011). Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice. Journal of Clinical Investigation, 121(4), 1329–1343.PubMedCentralPubMed

101.

Li, D. Q., Ohshiro, K., Reddy, S. D., Pakala, S. B., Lee, M. H., Zhang, Y., et al. (2009). E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proceedings of the National Academy of Sciences of the United States of America, 106(41), 17493–17498.PubMedCentralPubMed

102.

Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377–381.PubMed

103.

Ohshiro, K., Rayala, S. K., Wigerup, C., Pakala, S. B., Natha, R. S., Gururaj, A. E., et al. (2010). Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Reports, 11(9), 691–697.PubMedCentralPubMed

104.

Denslow, S. A., & Wade, P. A. (2007). The human Mi-2/NuRD complex and gene regulation. Oncogene, 26(37), 5433–5438.PubMed

105.

Mazumdar, A., Wang, R. A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3(1), 30–37.PubMed

106.

Hay, E. D. (1995). An overview of epithelio-mesenchymal transformation. Acta Anatomica, 154(1), 8–20.PubMed

107.

Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nature Reviews Molecular Cell Biology, 15(3), 178–196.PubMedCentralPubMed

108.

Medici, D., & Kalluri, R. (2012). Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Seminars in Cancer Biology, 22(5–6), 379–384.PubMedCentralPubMed

109.

van Meeteren, L. A., & ten Dijke, P. (2012). Regulation of endothelial cell plasticity by TGF-β. Cell and Tissue Research, 347(1), 177–186.PubMedCentralPubMed

110.

Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research, 67(21), 10123–10128.PubMed

111.

Lee, S. W., Won, J. Y., Kim, W. J., Lee, J., Kim, K. H., Youn, S. W., et al. (2013). Snail as a potential target molecule in cardiac fibrosis: paracrine action of endothelial cells on fibroblasts through snail and CTGF axis. Molecular Therapy, 21(9), 1767–1777.PubMedCentralPubMed

112.

Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., & Olsen, B. R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nature Medicine, 16(12), 1400–1406.PubMedCentralPubMed

113.

Wong, L. L., Chang, C. F., Koay, E. S., & Zhang, D. (2009). Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. International Journal of Oncology, 34(5), 1291–1301.PubMed

114.

Kim, R., Arihiro, K., Emi, M., Tanabe, K., & Osaki, A. (2006). Potential role of HER-2; in primary breast tumor with bone metastasis. Oncology Reports, 15(6), 1477–1484.PubMed

115.

Jiang, W. G., Lloyds, D., Puntis, M. C., Nakamura, T., & Hallett, M. B. (1993). Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor. Clinical and Experimental Metastasis, 11(3), 235–242.PubMed

116.

Jiang, W., Hiscox, S., Matsumoto, K., & Nakamura, T. (1999). Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology, 29(3), 209–248.PubMed

117.

Stoker, M., & Perryman, M. (1985). An epithelial scatter factor released by embryo fibroblasts. Journal of Cell Science, 77, 209–223.PubMed

118.

Savagner, P., Yamada, K. M., & Thiery, J. P. (1997). The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. Journal of Cell Biology, 137(6), 1403–1419.PubMedCentralPubMed

119.

Grotegut, S., von Schweinitz, D., Christofori, G., & Lehembre, F. (2006). Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO Journal, 25(15), 3534–3545.PubMedCentralPubMed

120.

Hiscox, S., & Jiang, W. G. (1999). Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochemical and Biophysical Research Communications, 261(2), 406–411.PubMed

121.

Pakala, S. B., Singh, K., Reddy, S. D., Ohshiro, K., Li, D. Q., Mishra, L., et al. (2011). TGF-β1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30(19), 2230–2241.PubMedCentralPubMed

122.

Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2(6), 442–454.PubMed

123.

Dannenmann, C., Shabani, N., Friese, K., Jeschke, U., Mylonas, I., & Brüning, A. (2008). The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biology and Therapy, 7(9), 1460–1467.PubMed

124.

Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., et al. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nature Cell Biology, 2(2), 84–89.PubMed

125.

Polyak, K., & Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer, 9(4), 265–273.PubMed

126.

Moon, E. J., Jeong, C. H., Jeong, J. W., Kim, K. R., Yu, D. Y., Murakami, S., et al. (2004). Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1α. FASEB Journal, 18(2), 382–384.PubMed

127.

Zhang, X. Y., DeSalle, L. M., Patel, J. H., Capobianco, A. J., Yu, D., Thomas-Tikhonenko, A., et al. (2005). Metastasis-associated protein I (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proceedings of the National Academy of Sciences of the United States of America, 102(39), 13968–13973.PubMedCentralPubMed

128.

Terradillos, O., Billet, O., Renard, C. A., Levy, R., Molina, T., Briand, P., et al. (1997). The hepatitis B virus X gene potentiates c-MYC induced liver oncogenesis in transgenic mice. Oncogene, 14(4), 395–404.PubMed

129.

130.

Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes and Development, 13(15), 1924–1935.PubMedCentralPubMed

131.

Park, N. H., Song, I. H., & Chung, Y. H. (2006). Chronic hepatitis B in hepatocarcinogenesis. Postgraduate Medical Journal, 82(970), 507–51.PubMedCentralPubMed

132.

Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998). Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 28(1), 68–77.PubMed

133.

Pang, R., & Poon, R. T. (2006). Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Letters, 242(2), 151–167.PubMed

134.

Song, B. C., Chung, Y. H., Kim, J. A., Lee, H. C., Yoon, H. K., Sung, K. B., et al. (2001). Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer, 91(12), 2386–2393.PubMed

135.

Li, H., Sun, L., Xu, Y., Li, Z., Luo, W., Tang, Z., et al. (2013). Overexpression of MTA3 correlates with tumor progression in non-small cell lung cancer. Plos One, 8(6), 1–8.

136.

Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12(5), 1479–1486.PubMed

137.

Dong, H., Guo, H., Xie, L., Wang, G., Zhong, X., Khoury, T., et al. (2013). The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. PloS One, 8(5), e62986.PubMedCentralPubMed

138.

Chu, H., Chen, X., Wang, H., Du, Y., Wang, Y., Zang, W., et al. (2014). MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumour Biology, 35(4), 3487–3494.PubMed

139.

Zhong, J. H., Ma, L., & Li, L. Q. (2014). Postoperative therapy options for hepatocellular carcinoma. Scandivian Journal of Gastroenterology, 49(6), 649–661.

140.

Shin, J. W., & Chung, Y. H. (2013). Molecular targeted therapy for hepatocellular carcinoma: current and future. World Journal of Gastroenterology, 19(37), 6144–6155.PubMedCentralPubMed

141.

Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Fukuda, M., et al. (1998). Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer, 82(5), 827–835.PubMed

142.

Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., et al. (1999). Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group Inhibition of Hepatocarcinogenesis by Interferon Therapy. Annals of Internal Medicine, 131(3), 174–181.PubMed

143.

Sun, H. C., Tang, Z. Y., Wang, L., Qin, L. X., Ma, Z. C., Ye, Q. H., et al. (2006). Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. Journal of Cancer Research and Clinical Oncology, 132(7), 458–465.PubMed

144.

Kudo, M. (2008). Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology, 75(suppl 1), 30–41.PubMed

145.

Zeisberg, M., Yang, C., Martino, M., Duncan, M. B., Rieder, F., Tanjore, H., et al. (2007). Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. Journal of Biological Chemistry, 282(32), 23337–23347.PubMed

146.

Kim, K. H., Lee, W. R., Kang, Y. N., Chang, Y. C., & Park, K. K. (2014). Inhibitory effect of nuclear factor-κB decoy oligodeoxynucleotide on liver fibrosis through regulation of the epithelial-mesenchymal transition. Human Gene Therapy, 25(8), 721–729.PubMed

Titel: Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine
verfasst von: Soo Hyung Ryu
Myoung Kuk Jang
Woo Jean Kim
Danbi Lee
Young-Hwa Chung
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9522-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Erratum to: Emerging strategies to overcome resistance to endocrine therapy for breast cancer

Clinical implications of MTA proteins in human cancer

Subcellular localization of MTA proteins in normal and cancer cells

Preface

Significance of MTA1 in the molecular characterization of osteosarcoma

E-cadherin germline mutation carriers: clinical management and genetic implications

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie